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Abstract Proadrenomedullin N-terminal 20 peptide (PAMP-
20) is a potent hypotensive peptide processed from the 
adrenomedullin (AM) precursor. We developed a specific radio-
immunoassay which recognizes the C-terminal region of PAMP-
20. Using this radioimmunoassay, the distribution of immuno-
reactive (ir-) PAMP was determined in porcine tissues. High 
concentrations of ir-PAMP were observed in the adrenal medulla 
and in the atrium, and these values were comparable to the 
corresponding concentrations of ir-AM. The concentration of ir-
PAMP was almost the same as that of ir-AM in the kidney, 
while ir-PAMP was significantly lower than ir-AM in the 
ventricle, lung, and aorta. Reversed-phase high performance 
liquid chromatography in each porcine tissue sample revealed 
that two major peaks of ir-PAMP existed: one emerged at a 
position identical to that of authentic porcine PAMP-20; the 
other unknown peak was eluted earlier. The unknown peptide 
was purified to homogeneity from porcine adrenal medulla, and 
its complete amino acid sequence was determined. This peptide 
was found to be PAMP[9-20] with a C-terminal amide structure, 
and was named PAMP-12. Intravenous injections of PAMP-12 
in anesthetized rats showed a significant hypotensive effect in a 
dose-dependent fashion, and the effect was comparable to that of 
PAMP-20. These data indicate that PAMP-12, a major 
component of ir-PAMP, is processed from the AM precursor, 
as is PAMP-20, and may participate in cardiovascular control. 
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1. Introduction 
Adrenomedullin (AM), originally isolated from human 
pheochromocytoma tissue [1], has been shown to possess a 
potent hypotensive action [1,2]. A cDNA cloning of an AM 
precursor (preproadrenomedullin) was carried out in humans, 
pigs, and rats [3-5]. The precursor of porcine AM consists of 
188 amino acids, including a 21-residue signal peptide at its 
N-terminus. The N-terminal portion of proadrenomedullin 
contains a unique 20-residue sequence, which is followed by 
the typical amidation signal of Gly-Lys-Arg. The peptide thus 
predicted was designated as proadrenomedullin N-terminal 20 
peptide (PAMP-20), whose C-terminus is amidated. 
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We previously established a radioimmunoassay (RIA) 
which recognizes the entire PAMP-20 molecule, but has little 
cross-reactivity with fragment peptides of PAMP-20 [6]. With 
the use of this RIA, the existence of PAMP-20 in vivo was 
demonstrated by the isolation and characterization of the pep-
tide from both human pheochromocytoma and porcine adre-
nal medulla [7,8]. PAMP-20 elicited a potent hypotensive ef-
fect when injected intravenously in anesthetized rats [8]. 
PAMP-20 also inhibited carbachol-induced catecholamine 
synthesis and secretion in cultured bovine adrenal medullary 
cells [9,10]. It has been reported that the vasodilating activity 
of PAMP-20 is due mainly to an inhibition of catecholamine 
release from peripheral sympathetic nerve endings in rat mes-
enteric artery [11]. These data indicate that PAMP may play a 
key role in cardiovascular control through a mechanism dif-
ferent from that of AM. 
Although both PAMP-20 and AM are produced from the 
same precursor, the immunoreactive (ir-) PAMP-20 concen-
trations in tissue and plasma, when assayed with the RIA 
recognizing the entire PAMP-20 molecule, were lower than 
those of ir-AM [6,12]. These data suggest that the biosynthesis 
or metabolism of PAMP may be different from that of AM. 
In the present study, to elucidate the biosynthesis and me-
tabolism of PAMP, we developed a new RIA which recog-
nizes the C-terminal region of PAMP. Using this RIA, we 
examined the distribution of ir-PAMP in porcine tissues. We 
also demonstrated that PAMP[9-20] (PAMP-12) is a major 
product of the AM precursor, as is PAMP-20, and that 
PAMP-12 possesses hypotensive activity comparable to that 
of PAMP-20. 
2. Materials and methods 
2.1. Synthetic peptides 
N-Tyr-PAMP[10-20], human PAMP[l-20] (PAMP-20), PAMP[9-
20] (PAMP-12), [10-20], [13-20], and [16-20] were synthesized by the 
solid phase method with a peptide synthesizer (Model 431 A, Applied 
Biosystems, Foster, CA, USA), and purified by reversed-phase high 
performance liquid chromatography (RP-HPLC). 
2.2. Preparation of antiserum against PAMP 
PAMP[10-20] (8 mg) and bovine thyroglobulin (10 mg) were con-
jugated by the carbodimide method as described [13]. The reaction 
mixture was dialyzed four times against one liter of 0.9% NaCl and 
twice against one liter of 0.05 M sodium phosphate buffer (pH 7.4) 
containing 0.08 M NaCl. The dialyzed solution was emulsified with an 
equal volume of Freund's complete adjuvant, then used for immuniz-
ing New Zealand white male rabbits as described [14]. 
2.3. Radioiodination of ligand 
N-Tyr-PAMP[10-20] was dissolved in 25 ul of 0.4 M sodium ace-
tate buffer (pH 5.6) in a reaction tube. Lactoperoxidase (Calbiochem, 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)00971-X 
106 
San Diego, CA, USA: 600 ng/10 ul of 0.1 M sodium acetate buffer, 
pH 5.6) and H 2 0 2 (70 ng/5 ul of water) were added to the reaction 
tube. After the tube was left standing for 10 min at 30°C, H 2 0 2 (70 
ng/5 ul of water) was added, and the tube was again left for 10 min at 
30°C. 125I-labeled peptide was purified by RP-HPLC on a TSK ODS 
120A column (4.6 X150 mm, TOSOH, Tokyo, Japan), then stored at 
-80°C after adding 1% bacitracin and 1% Triton X-100. 
2.4. RIA for PAMP and AM 
The RIA for PAMP[10-20] was carried out as follows. The RIA 
incubation buffer for PAMP was 0.05 M sodium phosphate buffer 
(pH 7.4) containing 0.5% bovine serum albumin, 0.5% Triton X-
100, 0.025 M EDTA-2Na, 0.05% NaN3, and 500 KlU/ml of aprotinin. 
The RIA incubation mixture was composed of 100 ul of the standard 
PAMP[ 10-20] or the unknown sample with 200 ul of an antiserum 
which contained 0.5% normal rabbit serum, which was designated 
PAMP Ab-M#6-3, at the dilution of 1:6650. After incubation for 
12 h, 100 itl of 125I-N-Tyr-PAMP[10-20]NH2 (18000 cpm) was added 
and incubated for 24 h. One hundred ul of anti-rabbit IgG goat serum 
diluent was then added, and incubation was continued for 24 h. The 
tubes were centrifuged at 2000 Xg at 4°C for 30 min, and the radio-
activity of the precipitate was measured with a gamma-counter (Aloka 
ARC-600, Tokyo). 
Ir-AM in the tissue sample was measured by an RIA for human 
AM using the previously described method [12]. This RIA has shown 
100% cross-reactivity with porcine AM. 
All assay procedures were done in duplicate at 4°C. 
2.5. Preparation of tissue samples 
The peptide extract was prepared by the method described previ-
ously [1]. Porcine adrenal medulla, atrium, ventricle, lung, kidney, and 
aorta were collected at a local slaughterhouse soon after killing. After 
weighing, each tissue sample (n = 4, each type of tissue) was boiled for 
10 min in 1 M acetic acid containing 20 mM HC1 to inactivate in-
trinsic proteases. After cooling, extractions were homogenized with a 
Polytron mixer at 4°C, and the mixture was centrifuged at 24000Xg 
at 4°C for 30 min. The supernatant solution was applied to a Sep-Pak 
C-18 cartridge column (1 ml, Waters, Milford, MA, USA) pre-equi-
librated with 0.5 M acetic acid, and the absorbed material was eluted 
with 4 ml of 60% CH3CN containing 0.1% trifluoroacetic acid (TFA). 
After lyophilization of the sample, the residue was dissolved in the 
RIA buffer for use in the RIAs for both PAMP and AM. 
2.6. Purification and structural analysis of PAMP-12 
Porcine adrenal medulla (12 g) was boiled for 10 min in 60 ml of 
1 M acetic acid containing 20 mM HC1. After cooling, the extractions 
were homogenized with a Polytron mixer at 4°C. The extract super-
natant obtained after a 30 -min centrifugation at 17000Xg was loaded 
onto a Sep-Pak C-18 cartridge column (20 ml, Waters). After washing 
the column with 0.5 M acetic acid, the materials absorbed on the 
column were eluted with 60% CH3CN containing 0.1% TFA, and 
the eluent was concentrated. In the subsequent purification procedure, 
an aliquot of each fraction was examined by the RIA for the C-
terminal region of PAMP-20. The concentrated solution was loaded 
onto a gel-filtration chromatography system (Sephadex G-50, fine, 
3 X 150 cm) which was equilibrated with 1 M acetic acid. The fractions 
containing ir-PAMP were then separated by RP-HPLC on a column 
of Chemcosorb 7-ODS-H (10X250 mm, Chemco, Osaka, Japan) (Fig. 
3A). The highest unknown peak of ir-PAMP, which emerged earlier 
than that of porcine PAMP-20, was further applied to ion-exchange 
HPLC on a column of TSK CM-2SW (4.0x300 mm, TOSOH) (Fig. 
3B). The fraction containing the major ir-PAMP was finally purified 
by RP-HPLC on a column of Chemcosorb 3-ODS-H (2.1x75 mm, 
Chemco) (Fig. 3C). The purified peptide was sequenced with a gas-
phase sequencer (Model 494, Applied Biosystems). The column efflu-
ents on the RP-HPLC were monitored by simultaneously measuring 
the absorbance at 210 and 280 nm. 
2.7. Hypotensive activity 
The depressor effect of PAMP-12 was examined by methods similar 
to those reported for human AM [2]. Seven-week-old male Wistar rats 
(ca. 300 g) were anesthetized by an intraperitoneal injection of sodium 
pentobarbital (50 mg/kg). Blood pressure was monitored continuously 
from a right carotid artery catheter (PE-50) connected to a Statham 
pressor transducer (Model P231D, Gould, Saddle Brook, NJ, USA). 
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A PE-10 catheter was inserted into the right jugular vein for the 
administration of both maintenance solution and peptides. After equi-
libration for at least 60 min, PAMP-12 or human PAMP-20 was 
injected intravenously. 
2.8. Statistical analysis 
All data are presented as means ±S.E.M. For the comparison of 
statistical significance between two groups, Student's Mest for un-
paired data was used. A value of P < 0.05 was accepted as significant. 
3. Results 
3.1. RIA for PAMP 
The antiserum to PAMP[10-20], P A M P Ab-M#6-3 , recog-
nized synthetic PAMP[ 10-20] with high affinity at a final di-
lution of 1:13 300. As shown in Fig. 1, the half-maximal in-
hibition of radio-iodinated ligand binding by PAMP[ 10-20] 
occurred at 30 fmol/tube. The measurable range of this R I A 
was from 2 to 256 fmol/tube. The intra- and inter-assay co-
efficients of variance were 6% and 9%, respectively. The dilu-
tion curve of the extracts of porcine adrenal medulla was 
roughly parallel to the standard curve of PAMP[10-20]. The 
R I A had 100% and 50% cross-reactivity with PAMP-12 and 
human PAMP-20, respectively, but had less than 0 .01% cross-
reactivity with PAMP[13-20] and [16-20]. 
3.2. Distribution of ir-PAMP and ir-AM in porcine tissues 
High concentrations of i r -PAMP in the adrenal medulla 
and in the atr ium were comparable to the corresponding con-
centrations of ir-AM (Table 1). The concentration of ir-
P A M P was almost the same as that of i r -AM in the kidney, 
while i r -PAMP was significantly (p < 0.05) lower than i r -AM 
in the ventricle, lung, and aorta. In the lung, the i r -PAMP 
concentration was only 8% of that of i r-AM. 
3.3. Characterization of ir-PAMP 
The characterization of i r -PAMP in the porcine adrenal 
1 10 100 1000 
Peptide (fmol/tube) 
Fig. 1. Standard curve of RIA for PAMP and cross-reactivity of 
antiserum. Inhibition of 125I-labeled human PAMP[10-20] binding 
to antiserum by serial dilutions of human PAMP[l-20] ( — A — ) , 
PAMP[9-20] and [10-20] ( - • - ) , [13-20] ( - O - ) , and [16-20] 
(-a—). PAMP[9-20] (PAMP-12) and human PAMP[l-20] (PAMP-
20) showed 100% and 50% cross-reactivity with antiserum. 
PAMP[13-20] and [16-20] exhibited less than 0.01% cross-reactivity 
with antiserum. The dilution curve of the porcine adrenal medulla 
sample (—A—) was parallel to the standard curve. 
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medulla and atrium, whose PAMP concentrations were abun-
dant, was performed by RP-HPLC, coupled with the present 
RIA for PAMP. As shown in Fig. 2, an unknown major peak 
emerged at 22 min in both tissues. The elution time was 8 min 
earlier than that of synthetic porcine PAMP-20. The unknown 
major immunoreactivity was approximately twice as high as 
that of ir-PAMP-20. The unknown peak was therefore puri-
fied to determine its complete amino acid sequence, using 
porcine adrenal medulla which contained a high PAMP con-
centration. 
3.4. Isolation and structural analysis 
The unknown major peak of ir-PAMP in the porcine adre-
nal medulla extract was purified to homogeneity using the 
present RIA for PAMP. In gel-filtration chromatography 
analysis, one ir-PAMP peak was observed at Mr 1500-2500. 
These fractions containing ir-PAMP were further separated by 
RP-HPLC. As shown in Fig. 3A, two major peaks of ir-
PAMP were found: One (peak II) emerged at a position iden-
tical to that of synthetic porcine PAMP-20; the other un-
known peak (peak I) emerged earlier and contained a 1.8-
fold greater amount of ir-PAMP-20. The unknown major 
peak was applied to ion-exchange HPLC. A major ir-PAMP 
peak was eluted later than that of synthetic porcine PAMP-20 
(Fig. 3B). The fraction containing the unknown major ir-
Table 1 
Regional distributions of ir-PAMP and ir-AM in porcine tissue 
10 20 30 
Time (min) 
Fig. 2. Characterization of ir-PAMP by RP-HPLC. Sample: (a) 
adrenal medulla (8 mg eq.), (b) atrium (1.6 g eq.). Column: TSK 
ODS 120A, 4.6X150 mm. Flow rate: 1.0 ml/min. Solvent system: 
(a) H2O:CH3CN:10% TFA = 90:10:1; (b) H2O:CH3CN:10% 
TFA = 40:60:1. Linear gradient from (a) to (b) for 60 min. The ar-
row shows the elution position of porcine PAMP-20. 
Region 
Adrenal medulla 
Heart atrium 
Heart ventricle 
Lung 
Kidney 
Aorta 
ir-PAMP 
222.3 ±27.2 
1.50 ±0.36 
0.14 ±0.02 
0.13 ±0.02 
0.19±0.01 
0.11 ±0.01 
ir-AM 
205.4±15.4 
1.56±0.37 
0.24 ±0.02* 
4.28 ±0.17* 
0.29 ±0.03 
0.22 ±0.04* 
Results are expressed as fmol/mg wet tissue. All values are means 
±S.E.M. of four samples. *P<0.05 vs. ir-PAMP. 
PAMP was finally purified by RP-HPLC. The HPLC yielded 
a homogeneous peptide peak (Fig. 3C). The recovery of this 
peptide was 90 pmol, starting from 12 g of porcine adrenal 
medulla. 
Half of the purified peptide was subjected to a gas-phase 
automated sequencer. Its complete amino acid sequence was 
identified as Phe-Arg-Lys-Lys-Trp-Asn-Lys-Trp-Ala-Leu-Ser-
Arg (Table 2). The yield of Trp, Ser, and Arg was too low to 
give accurate values, although they appeared in detectable 
amounts. Thus, the major immunoreactive peptide was iden-
tified as PAMP[9-20], which lacked eight amino acids at the 
N-terminal site of PAMP. This peptide was named PAMP-12. 
The C-terminus of Arg was found to be amidated; the 
elution position of this peptide in RP-HPLC and ion-ex-
change HPLC was found to be identical to that of synthetic 
PAMP-12. 
3.5. Hypotensive effect 
The hypotensive effects of the PAMPs in anesthetized rats 
are demonstrated in Fig. 4. The intravenous bolus injection of 
PAMP-12 in doses of 10 to 50 nmol/kg caused a significant 
hypotensive effect in a dose-dependent manner. When PAMP-
12 at 50 nmol/kg was injected intravenously, the maximum 
decrease of mean blood pressure was 39.7 ± 3.8 mmHg (n = 6). 
The hypotensive activity of PAMP-12 did not differ signifi-
cantly from that of human PAMP-20. 
4. Discussion 
In this study, we established an RIA for the C-terminal 
region of PAMP, and demonstrated the regional distribution 
of ir-PAMP in porcine tissues. We also identified PAMP-12 in 
porcine adrenal medulla as a major endogenous hypotensive 
peptide from the AM precursor. 
The distribution of PAMP was similar to that of AM, im-
plying that PAMP is biosynthesized from the AM precursor. 
The concentration of ir-PAMP was comparable to that of ir-
AM in the adrenal medulla, atrium, and kidney. Unexpect-
edly, however, its value was less than half of that of ir-AM in 
other tissues. These data suggest that the mechanism of bio-
synthesis or metabolism of PAMP may be different among 
these tissues. 
It is noteworthy that the ir-PAMP concentration in the 
lungs was very low, compared to ir-AM. Owji et al. reported 
that rat lung has the most abundant binding sites of AM, 
about seven-fold that of the adrenal gland [15]. Additionally, 
in patients with ischemic heart disease, the plasma concentra-
tion of AM in the aorta was significantly lower than that in 
the pulmonary artery, suggesting that pulmonary circulation 
may be one of the important sites for endogenous AM clear-
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Fig. 3. Purification of porcine adrenal medulla monitored by RIA for PAMP. (A) Reversed-phase HPLC. Sample: Immunoreactive (ir-) PAMP 
obtained from 12 g porcine adrenal medulla tissue by gel-filtration (Sephadex G-50). Column: Chemcosorb 7-ODS-H, 10x250 mm. Flow rate: 
2.0 ml/min. Solvent system: Linear gradient from (A) to (B) for 120 min. (A) and (B): the same as Fig. 2. Peak 1:380 pmol or ir-PAMP; Peak 
11:210 pmol of PAMP-20. (B) CM ion-exchange HPLC. Sample: peak I in A. Column: TSK CM-2SW, 4.0x300 mm. Flow rate: 1.0 ml/min. 
Solvent system: (A) 10 mM HCOONH4 (pH 6.5): CH3CN = 90:10 (V/V); (B) 1 M HCOONH4 (pH 6.5):CH3CN = 90:10 (V/V). Linear gra-
dient from (A) to (B) for 60 min. The arrow shows the elution position of porcine PAMP-20. (C) Final purification of ir-PAMP by RP-HPLC. 
Sample: major ir-PAMP in B. Column: Chemcosorb 3-ODS-H, 2.1x75 mm. Flow rate: 0.2 ml/min. Solvent system: Linear gradient from (A) 
to (B) for 80 min. (A) and (B): the same as Fig. 2. Absorbance at 210 nm (—) was monitored. Black bar indicates 90 pmol of ir-PAMP. 
ance [16]. In contrast, PAMP receptors in the rat lung is one-
fifth of that in the adrenal gland [17]. The difference of re-
ceptor binding sites for AM and PAMP may be the main 
contributor to the discrepancy of immunoreactive concentra-
tions between these pep tides. 
Here we purified 90 pmol of PAMP-12, starting from 12 g 
of porcine adrenal medulla which contained 1850 pmol of 
total ir-PAMP. The low recovery of purified PAMP-12 is 
probably due to its strong basic and hydrophobic character-
istics. However, a major component of ir-PAMP in adrenal 
medulla must be PAMP-12, because the purified ir-PAMP 
was eluted at the same position where the major ir-PAMP 
in the crude adrenal medulla extract was eluted. In addition, 
the recovery rate of ir-PAMP-12 in each purification step after 
the initial RP-HPLC analysis was more than 46%. We thus 
purified the major ir-PAMP peaks from porcine adrenal me-
dulla. 
The structure of PAMP-12, determined by sequence analy-
ses (Table 2), was further confirmed by HPLC analyses of 
purified PAMP and synthetic PAMP. Since the elution pro-
files of the two peptides were identical on RP-HPLC and ion-
exchange HPLC, the purified peptide in porcine adrenal me-
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Fig. 4. Hypotensive responses of anesthetized rats to intravenous 
bolus injections of PAMPs. A bolus injection of PAMP-12 caused a 
significant hypotensive effect in a dose-dependent fashion. The maxi-
mum decrease of mean blood pressure (MBP) (n = 6) was 39.7 ± 3.8 
mmHg for 50 nmol/kg. The hypotensive activity of PAMP-12 did 
not differ significantly from that of human PAMP-20. 
dulla is identical to synthetic PAMP-12 with an amidated 
carboxy terminus. 
Since the previous RIA for the entire PAMP-20 molecule 
showed only 19% cross-reactivity with PAMP-12 [6], the ex-
istence of PAMP-12 in vivo was not identified in previous 
studies [7,8]. In the present study, the immunoreactive peak 
of PAMP-12 was demonstrated to be reproducibly higher 
than that of PAMP-20 by the RP-HPLC analyses, indicating 
that this peptide exists in vivo as an endogenous peptide. In 
the adrenal medulla and atrium, in particular, the ir-PAMP-
12 concentration was approximately twice as high as that of 
ir-PAMP-20 (Fig. 2). The new RIA for the C-terminal region 
of PAMP-20 showed 100% and 50% cross-reactivity with 
PAMP-12 and PAMP-20, respectively. These findings indicate 
Table 2 
Amino acid sequence determination of isolated peptide 
Cycle number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Peptide 
Phe 
Arg 
Lys 
Lys 
Trp 
Asn 
Lys 
Trp 
Ala 
Leu 
Ser 
Arg 
(pmol) 
3.30 
1.05 
1.86 
1.99 
0.97 
2.16 
0.83 
0.70 
that the presence of PAMP-12 and that of PAMP-20 are 
comparable in both tissues. Further studies are required to 
elucidate the mechanism by which PAMP-12 is biosynthesized 
in vivo. 
We previously demonstrated that PAMP-20 shows a potent 
hypotensive activity [8], and that its plasma concentration is 
increased in spontaneously hypertensive rats and in patients 
with congestive heart failure or renal failure [18-20]. In the 
present study, it was found that PAMP-12 also had a signifi-
cant hypotensive action, comparable to that of PAMP-20. 
PAMP[10-20] also showed considerable hypotensive activity, 
but PAMP[16-20] and PAMP without the C-terminal amide 
structure showed little hypotensive activity (unpublished ob-
servations). The sequence between the 9th and 20th amino 
acid of PAMP-20 is well conserved among species [3-5]. Tak-
en together, these findings suggest that the C-terminal region 
including the amide structure of PAMP plays an important 
role in the biological activity of PAMP. 
In conclusion, we have identified PAMP-12 in porcine adre-
nal medulla as a major product of the AM precursor, and 
demonstrated that it exhibits a potent hypotensive action. 
Although the existence of a specific receptor for PAMP-12 
and PAMP-20 remains obscure, PAMP-12 might share a bio-
logical function with PAMP-20. 
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